Dianthus Therapeutics: Clinical Momentum, Pipeline Expansion, and Undervalued Catalysts Support Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on DNTH stock, giving a Buy rating on January 8.

Myles Minter has given his Buy rating due to a combination of factors that highlight both strong execution and attractive valuation for Dianthus Therapeutics. He points to the compelling proof-of-concept data for claseprubart in generalized myasthenia gravis, which supports its potential as a best-in-class complement inhibitor and a pipeline-in-a-product across several autoimmune neurology indications. This strong profile appears to be validated by rapid patient enrollment in the CAPTIVATE trial in CIDP, especially when contrasted with slower enrollment and delayed timelines for a key competitor program at Sanofi. He also notes that upcoming readouts in CIDP and multifocal motor neuropathy in 2026 create a dense schedule of potential value-creating catalysts.

Minter further emphasizes that Dianthus’s recent acquisition of DNTH212 adds another first-in-class, yet mechanistically de-risked, asset that similarly carries multi-indication potential, improving diversification and long-term growth prospects. In his view, the market is not fully reflecting these opportunities, particularly when benchmarked against the commercial success of Argenx’s Vyvgart in CIDP and encouraging early data seen with C1s inhibitors more broadly. Taken together—robust clinical momentum, a broadened pipeline, multiple upcoming data catalysts, and a valuation he sees as too low—support his conviction that the shares merit a Buy rating.

In another report released on January 8, Truist Financial also maintained a Buy rating on the stock with a $63.00 price target.